Abstract:Abstract Background: Immune checkpoint blockade (ICB) therapies exhibit distinct response in hepatocellular carcinoma (HCC) patients, therefore biomarkers to screen beneficial patients remains an urgent need in clinical practice. Ferroptosis, an unique form of programmed cell death (PCD), has been implicated in the carcinogenesis and considered as one of the underlying mechanism of targeted and chemotherapeutic therapies in HCC. N6-methyladenosine (m6A), the most dominant form of RNA post-transcriptional modification, has been reported to regulat cancer-associated genes, including ferroptosis-related genes. Methods: Differentially expressed genes (DEGs) between tumor and normal tissues were screened from TCGA-LIHC dataset. The overlap of DEGs and ferroptosis-related genes (FRGs) resulted in a set of 51 genes. These genes together with 22 m6A-related genes were next subjected to univariate Cox regression for their association with survival. In total, 35 genes showed significant association with survival in this analysis, and they were then used to construct the regression model by Lasso-Cox regression analysis. We then validated the performance of the signature derived from the model in TCGA-LIHC and an external dataset (GSE14520). The signature was also examined for their association with immune-related characters, and their performance in predicting drug response using datasets of immunotherapy cohort studies and cellular experimental studies. Results: We constructed this prognosis model by expression level of four genes (G6PD, YTHDF1, STMN1, and SLC7A11). Patients with a high-risk score of the signature have a shortened survival time, and the signature is an independent predictor of the prognosis. We also found that the difference between the risk score before and after ICB treatment was significantly associated with sensitivity to the treatment: an increase in the risk score after the treatment correlated with an adverse response. Using the in vitro cellular experimental dataset, we detected a positive association between the risk score and the sensitivity to 5-fluorouracil and sorafenib. Conclusion: The prognosis signature constructed by four ferroptosis- and m6A- related genes exhibited promising predictive value for OS of HCC patients. The signature could also indicate the sensitivity for different kinds of clinical treatment. A higher risk score indicated a higher resistance for immunotherapy but a higher sensitivity for chemotherapy and RTKs inhibitor. The results of this study not only help to improve the clinical practice of HCC, but also provide new insights into unveiling the underlying mechanisms of tumorigenesis and progression. Citation Format: Tao Han, Mengyuan Liu. Model constructed by ferroptosis-related genes and m6A genes predicts the sensitivity to different drug treatments [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6559.

APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis

Integrated bioinformatics analysis identifies a Ferroptosis-related gene signature as prognosis model and potential therapeutic target of bladder cancer

Intratumor APOL3 delineates a distinctive immunogenic ferroptosis subset with prognosis prediction in colorectal cancer

Development and Validation of Ferroptosis-Related LncRNA Biomarker in Bladder Carcinoma

Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer

Identification of a Novel Ferroptosis-Related Gene Signature for Prediction of Prognosis in Bladder Urothelial Carcinoma

Ferroptosis-Related Long Noncoding RNAs Have Excellent Predictive Ability for Multiomic Characteristics of Bladder Cancer

Construction and External Validation of a Ferroptosis-Related Gene Signature of Predictive Value for the Overall Survival in Bladder Cancer

A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer

Abstract P6-11-13: Ferroptosis Heterogeneity in Triple-Negative Breast Cancer Reveals an Innovative Immunotherapy Combination Strategy

Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer Through Machine Learning Algorithm

A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Bladder cancer

Identification of a Ferroptosis-Related Long Noncoding RNA Prognostic Signature and Its Predictive Ability to Immunotherapy in Hepatocellular Carcinoma

Biological Functions and Prognostic Value of Ferroptosis-Related Genes in Bladder Cancer

Abstract 6559: Model constructed by ferroptosis-related genes and m6A genes predicts the sensitivity to different drug treatments

Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients

Identification of Clinical Prognostic Regulators and Analysis of Ferroptosis-Related Signatures in the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma

A novel signature constructed by ferroptosis-associated genes (FAGs) for the prediction of prognosis in bladder urothelial carcinoma (BLCA) and associated with immune infiltration

Integrating single-cell transcriptomics to reveal the ferroptosis regulators in the tumor microenvironment that contribute to bladder urothelial carcinoma progression and immunotherapy

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts

Identification and validation of an immunotherapeutic signature for colon cancer based on the regulatory patterns of ferroptosis and their association with the tumor microenvironment